medcareernews.com
FDA approves Lynparza for metastatic breast cancer - MedCareer News
LYNPARZA APPROVED BY US FDA IN GERMLINE BRCA-MUTATED METASTATIC BREAST CANCER Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced...